Tenderwize
Zurück zur Suche

Medicinal product with active combination Formoterol, Glycopyrroniumbromide and Beclometason (ATC R03AL09)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2028 · 583 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Wirkstoffkombination Formoterol, Glycopyrroniumbromid und Beclometason (ATC-Code: R03AL09)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

Contracts may be terminated early if AOK Sachsen-Anhalt decides to tender exclusive contracts for the same active ingre...

The notice explicitly states it is not a public procurement under GWB/EU directives, so legal remedies under procuremen...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for finished medicinal products with active combination Formoterol, Glycopyrroniumbromide and Beclometason (ATC R03AL09)
  • Open-house model: any eligible pharmaceutical company can conclude a contract at any time under uniform conditions
Vollständige Zusammenfassung anzeigen

Non-exclusive discount agreement (open-house model) for pharmaceutical products with active combination Formoterol, Glycopyrroniumbromide and Beclometason (ATC R03AL09) by AOK Sachsen-Anhalt. The procedure is explicitly not a public procurement under GWB, published for transparency. Any eligible pharmaceutical company can join at any time under uniform conditions. Contract duration up to 24 months, earliest start 01.06.2026, end 31.05.2028. No estimated value or award criteria provided.

Risiken

Contracts may be terminated early if AOK Sachsen-Anhalt decides to tender exclusive contracts for the same active ingre...

The notice explicitly states it is not a public procurement under GWB/EU directives, so legal remedies under procuremen...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Administrative

  • Interested pharmaceutical companies must request participation documents and the contract from the contact address
  • Participation requires fully completed and signed participation documents
  • Submission of documents via postal mail or electronically with qualified electronic signature (eIDAS) to [email protected]

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal product with active combination Formoterol, Glycopyrroniumbromide and Beclometason (ATC R03AL09)

Non-exclusive discount agreement under §130a(8) SGB V for the specified active combination, open-house model with anytime accession. No exclusivity, no individual negotiations. Contract ends 31.05.2028 regardless of start date; may be terminated earlier if exclusive contracts are tendered.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline Mar 30, 2028

Vergabedetails

Veröffentlichungsdatum
20 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
272002-2026

Dokumente (1)

Ähnliche Ausschreibungen